Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page Next › Last page Last »
Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More
Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More
Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More
Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More
Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More
